BioWorld

July 17, 2008

MacroGenics Boosts Anticancer Pipeline with Raven Acquisition

In a deal to be announced Thursday morning, MacroGenics Inc. is bolstering its anticancer antibody pipeline with the acquisition of Raven Biotechnologies Inc. (BioWorld Today) Read More

Optimer's Prulifloxacin Data Positive in First Phase III Study

Same Receptor is Helpful, Harmful for HIV Infection

BioAlliance Stops Doxorubicin Trial After Pulmonary Reactions

Jazz $26M Stock Sale to Fund Luvox Commercialization

PTC Gets $25M From Nonprofit to Fund Cystic Fibrosis Studies

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 4, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

EASL 2026: Emerging liver disease targets to watch

BioWorld

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...